Physician profile
James Alan Keating
NPI 1275533168
$2,786.03
in general payments reported to CMS, 2019-2025
28 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $587 · 2021: $613 · 2022: $276 · 2023: $259 · 2024: $320 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $978 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $977.94 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $331.99 | 2019-2022 | |
| Pfizer INC. | $265.36 | 2019-2022 | |
| Amgen INC. | $239.70 | 2022-2024 | Repatha, Otezla |
| Corcept Therapeutics | $218.83 | 2023-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.90 | 2019-2025 | Jardiance, Tradjenta |
| Allergan, INC. | $188.15 | 2019-2020 | |
| Abbvie INC. | $187.76 | 2020-2022 | |
| Novo Nordisk INC | $136.61 | 2020-2022 | |
| Lilly USA, LLC | $136.04 | 2020-2025 | Jardiance |
| Abbott Laboratories | $114.52 | 2021-2022 | |
| Eisai INC. | $93.71 | 2020-2025 | |
| Glaxosmithkline, LLC. | $88.85 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $83.78 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.57 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $58.59 | 2019-2025 | Airsupra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $50.83 | 2021-2022 | |
| Almatica Pharma LLC | $44.63 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $41.76 | 2023 | Nexletol, Contrave, Nexlizet |
| Recordati_rare_diseases_inc. | $37.91 | 2025 | Isturisa |
| Exact Sciences Corporation | $30.48 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $25.02 | 2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $24.63 | 2021 | |
| Xeris Pharmaceuticals, INC. | $24.46 | 2025 | Recorlev |
| Esperion Therapeutics, INC. | $22.20 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.11 | 2025 | Xifaxan |
| Lundbeck LLC | $18.78 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $17.56 | 2022 | |
| Astellas Pharma US INC | $16.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Keating listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.